Stock Events

Stock Events

Genprex 

0
102
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2DecExpected
Q4 2025
Q2 2026
Next
-249.69
-249.36
-249.03
-248.69
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-14.1MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2DE1.MU. It's not an investment recommendation.
Amazon
15
AMZN
Apple
13
AAPL
NVIDIA
13
NVDA
Microsoft
12
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. has a broad portfolio of cancer therapies, including gene therapies, making it a major competitor in the oncology market.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics AG is a leader in gene editing technology, which can be applied to cancer treatment, making it a competitor in the gene therapy market.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics, Inc. is involved in CRISPR/Cas9 gene editing, a cutting-edge technology for treating genetic diseases and cancer, competing with Genprex's gene therapy approach.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine, Inc. works on gene editing technologies, including CRISPR, for the treatment of serious diseases, offering an alternative to Genprex's therapies.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals, Inc. focuses on RNAi (RNA interference) therapeutics for the treatment of genetic diseases, indirectly competing with Genprex's gene therapy approach by offering a different method of genetic intervention.

About

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Show more...
CEO
Ryan Confer
Employees
13
Country
United States
ISIN
US3724464017
WKN
000A42FVZ

Listings

STU
DE
2DE.STU
F
DE
2DE1.F
LSE
GB
0A8I.LSE
MU
DE
2DE1.MU

0 Comments

Share your thoughts

FAQ

What is Genprex stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Genprex stocks are traded under the ticker 2DE1.MU.
When is the next Genprex earnings date?▼
Genprex is going to release the next earnings report on December 02, 2026.
What is Genprex revenue for the last year?▼
Genprex revenue for the last year amounts to 0 EUR.
What is Genprex net income for the last year?▼
2DE1.MU net income for the last year is -14.1M EUR.
How many employees does Genprex have?▼
As of September 04, 2026, the company has 13 employees.
In which sector is Genprex located?▼
Genprex operates in the Health & Wellness sector.
When did Genprex complete a stock split?▼
The last stock split for Genprex was on July 16, 2026 with a ratio of 1:22.
Where is Genprex headquartered?▼
Genprex is headquartered in AUSTIN, United States.